Collegium Pharmaceutical, Inc. (COLL) - Stock Analysis

Last updated: Sep 19, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Shares gained 9.6% through November 19; Q3 earnings and revenue beat consensus, JORNAY PM sales grew 24%, and the company completed a $50 million share repurchase.

Loading chart data...

Idea window: 11/20/2026 – 11/27/2026Sector: Healthcare

AI Analyst Overview

Last Price
$24.72
Market Cap
$768.18M
1D Return
-1.94%
YTD Return
-46.61%

Loading chart data...

Valuation Metrics

P/E
20.3
P/B
2.6
P/S
0.9
EV/EBITDA
4.8
Div Yield
—

Fundamental Analysis

4.0

Key Financial Insights: • Margin Compression • Rising Leverage • Positive Cash Flow COLL's strong FY2025 profitability has deteriorated sharply into a quarterly loss with weaker margins, strained liquidity, and higher leverage, despite positive operating cash flow.

LiquidityRisk
CashFlow

Price Behavior

3.0

Key Price Behavior Insights: • Lower highs • Three-day rebound • Key support Support Level: $21.84 Resistance Level: $23.36–$23.70 COLL remains in a bearish last-month trend despite a tentative three-day rebound; hold above $21.84, but a move through $23.36–$23.70 is needed to confirm stabilization.

bearish
rebound

Sentiment & News

6.0

Key News Insights: • BlackRock stake • Price decline • Investor engagement • News View: Large institutional positions may support sentiment, but near-term share performance remains volatile. Collegium shares weakened despite major new institutional buying and ongoing investor outreach, signaling improved long-term interest amid near-term pressure.

InstitutionalBuying
ShareWeakness
AI

AI Summary

5.0
Neutral

COLL is a leveraged ADHD-platform transition—not a simple value play—where JORNAY PM and AZSTARYS growth can unlock significant upside only if margin recovery and free-cash-flow-driven deleveraging materially improve interest coverage; investors should prioritize quarterly EBITDA, cash conversion, and net-debt reduction over buybacks.

ADHDGrowth
LeverageRisk
MarginRecovery
AI summary updated 62 days ago

Description

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and markets prescription treatments for pain management. Its offerings include an abuse-deterrent extended-release oxycodone formulation and both immediate- and extended-release tapentadol products intended for severe, long-term, around-the-clock pain control. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Nov 20Nov 27COLLCollegium Pharmaceutical, Inc.
Shares gained 9.6% through November 19; Q3 earnings and revenue beat consensus, JORNAY PM sales grew 24%, and the company completed a $50 million share repurchase.
Active+0.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.